Co-targeting a MYC-eIF4A survival axis improves the efficacy of KRAS inhibitors in lung cancer. Nardi F, Perurena N, Schade AE, Li ZH, et al. J Clin Invest 2023 Jun 29:e167651. doi: 10.1172/JCI167651.

Read + Share

Amedeo Smart

Independent Medical Education

Nardi F, Perurena N, Schade AE, Li ZH, et al. Co-targeting a MYC-eIF4A survival axis improves the efficacy of KRAS inhibitors in lung cancer. J Clin Invest 2023 Jun 29:e167651. doi: 10.1172/JCI167651.
PMID: 37384411